Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Apollo Healthcare Corp Warrants (03/01/2022) APHWF

Based in Ontario Canada the Apollo Healthcare Corp Apollo is one of the largest private label personal care product manufacturers in North America developing and manufacturing retailer branded and private label products for major North American retailers. Apollos products are sold in tens of thousands of stores across North America and its customer base spans across major North American grocery drug and mass merchandise retailers users as well as wholesale clubs. In addition to private label Apollo also manufactures products on a contract basis for many of its clients.


OTCPK:APHWF - Post by User

Post by profitprophet1on Mar 15, 2021 5:57pm
132 Views
Post# 32804154

Earnings Now Released

Earnings Now Released
  •  
  •  
     
 
 
  •  
     
  •  
     

Apollo Healthcare Corp. (formerly Acasta Enterprises Inc.) (TSX: AHC, OTC QX: AHCCF) ("Apollo" or the "Company") today announced financial results for the quarter and year ended December 31, 2020.

The Company’s audited consolidated financial statements for the three months and year ended December 31, 2020, as well as its accompanying management discussion and analysis (MD&A) have been filed on SEDAR. Copies of the filings may be obtained at www.sedar.com. All values in this news release and the Company’s financial disclosures are in Canadian dollars unless otherwise stated.

Financial Highlights

  • Revenues for the fourth quarter of 2020 were $87.2 million and $321.7 million year to date compared with $41.8 million and $167.1 million in the comparative 2019 periods. The higher revenue is the result of higher volumes sold of the Company’s products.

  • EBITDA for the fourth quarter of 2020 was $25.2 million and $94.8 million year to date compared with EBITDA of negative $1.7 million and $11.3 million in the comparative 2019 periods. The improved results reflect higher volumes sold of the Company’s products.

  • Adjusted EBITDA for the fourth quarter of 2020 was $26.2 million and $91.2 million year to date compared with adjusted EBITDA of negative $0.9 million and $9.6 million in the comparative 2019 periods. Adjusted EBITDA removes the effects of foreign exchange, changes in fair value of financial instruments and impairment charges.

  • The Company retired all debt during year ended December 31, 2020. The Company has access to a $50 million revolver from its commercial bank should it require additional liquidity.

 

Please refer to Apollo’s MD&A for additional detail and discussion on the Company’s results from operations.


  •  
  •  
     
 
 
  •  
     
  •  
     

Apollo Healthcare Corp. (formerly Acasta Enterprises Inc.) (TSX: AHC, OTC QX: AHCCF) ("Apollo" or the "Company") today announced financial results for the quarter and year ended December 31, 2020.

The Company’s audited consolidated financial statements for the three months and year ended December 31, 2020, as well as its accompanying management discussion and analysis (MD&A) have been filed on SEDAR. Copies of the filings may be obtained at www.sedar.com. All values in this news release and the Company’s financial disclosures are in Canadian dollars unless otherwise stated.

Financial Highlights

  • Revenues for the fourth quarter of 2020 were $87.2 million and $321.7 million year to date compared with $41.8 million and $167.1 million in the comparative 2019 periods. The higher revenue is the result of higher volumes sold of the Company’s products.

  • EBITDA for the fourth quarter of 2020 was $25.2 million and $94.8 million year to date compared with EBITDA of negative $1.7 million and $11.3 million in the comparative 2019 periods. The improved results reflect higher volumes sold of the Company’s products.

  • Adjusted EBITDA for the fourth quarter of 2020 was $26.2 million and $91.2 million year to date compared with adjusted EBITDA of negative $0.9 million and $9.6 million in the comparative 2019 periods. Adjusted EBITDA removes the effects of foreign exchange, changes in fair value of financial instruments and impairment charges.

  • The Company retired all debt during year ended December 31, 2020. The Company has access to a $50 million revolver from its commercial bank should it require additional liquidity.

 

Please refer to Apollo’s MD&A for additional detail and discussion on the Company’s results from operations.


<< Previous
Bullboard Posts
Next >>